Algeria Device Classification: Class I, IIa, IIb, III

1. Key takeaways

The classification of devices in Algeria is written in Article 17 of Décret exécutif n° 20-324 and has four classes: Classe I (low risk), Classe IIa (moderate risk), Classe IIb (high risk) and Classe III (very high risk). The criterion is the potential risk of the device to the patient, and Article 17 additionally requires account to be taken of the evolution of international consensus.

Classification is not a formality. Articles 9 and 10 of the May 10, 2021 regularization ministerial order split Classes I/IIa and Classes IIb/III into two different evaluation pathways: the former follows a lighter assessment, while the latter goes through the four-phase complete technical evaluation of Article 25. Getting the class wrong therefore changes not just a label but the entire review experience and timeline.

In practice, the class also drives budget: lighter assessment means fewer data requests and fewer committee cycles, while the full evaluation route requires complete technical documentation from day one. GRZAN treats the classification file as a strategic document, prepared with the same care as the clinical or performance data itself.

2. Legal basis

1. Décret exécutif n° 20-324 du 6 Rabie Ethani 1442 correspondant au 22 novembre 2020 relatif aux modalités d’homologation des dispositifs médicaux (Executive Decree No. 20-324 of 6 Rabie Ethani 1442 corresponding to November 22, 2020 on the modalities of homologation of medical devices, JORADP No. 69, published 2020-11-22, pages 10–14, 46 articles), Article 17 (the four classes and the requirement to take account of the evolution of international consensus).
2. Arrêté du 28 Ramadhan 1442 correspondant au 10 mai 2021 fixant les modalités de régularisation du dossier d’homologation des dispositifs médicaux à usage de la médecine humaine (Ministerial Order of 28 Ramadhan 1442 corresponding to May 10, 2021 fixing the modalities of regularization of the homologation dossier for medical devices for human medicine, JORADP No. 55, published 2021-07-14, pages 24–26, 14 articles), Article 9 (the four situations subject to simplified technical evaluation for Classes I and IIa) and Article 10 (Classes IIb and III are subject to the complete evaluation of Article 25).
3. Décret exécutif n° 20-324 du 6 Rabie Ethani 1442 correspondant au 22 novembre 2020 relatif aux modalités d’homologation des dispositifs médicaux (JORADP No. 69, published 2020-11-22, pages 10–14, 46 articles), Article 25 (the four phases of technical evaluation).
4. Arrêté du 28 Ramadhan 1442 correspondant au 10 mai 2021 fixant la composition du dossier d’homologation et du dossier de renouvellement de la décision d’homologation des dispositifs médicaux à usage de la médecine humaine (Ministerial Order of 28 Ramadhan 1442 corresponding to May 10, 2021 fixing the composition of the homologation dossier and of the renewal dossier, JORADP No. 55, published 2021-07-14, pages 21–24, 13 articles), Article 4 (the dossier must state the classification and the classification rules).

3. Expert insights

Insight one: the four class names match the EU, but the legislative path is independent.

The naming I / IIa / IIb / III is identical to the EU device regulations, and GRZAN typically uses an existing EU classification conclusion as the starting point. But note: Article 17 states only the result and the principle of classification; it does not transplant the twenty-two EU classification rules. A CE certificate is therefore strong supporting reasoning, not an automatically accepted conclusion. Reviewers may still ask why a particular rule was applied, and the answer must be grounded in the potential-risk principle of Article 17.

Insight two: a classification error is caught at the admissibility stage.

Article 4 of the May 10, 2021 dossier order lists the classification and classification rules of the device as a mandatory dossier item, and both the admissibility review of the regularization track under Article 6 and of the standard track under Article 22 check dossier completeness. A wrong classification equals a missing dossier item and leads to rejection of the dossier within 8 days. The cost of that outcome is a full resubmission cycle, which is why the classification page deserves independent verification before filing.

Insight three: the lighter assessment for I / IIa has four cumulative conditions, not just the class.

Article 9 of the regularization order lists the situations eligible for simplified assessment, including: Classes I and IIa; manufacture and testing within a licensed pharmaceutical establishment and a licensed quality-control laboratory; importation under the import plan of a licensed import establishment; and no vigilance signals issued for the device in the country of origin or in Algeria. All four conditions must be met simultaneously before the lighter assessment applies; a vigilance record anywhere blocks the fast lane even for a Class I product.

Insight four: IVDs have no separate classification table and follow the same four-class system.

The current texts do not provide an independent classification rule set for IVDs. GRZAN handles this by grading IVDs under the potential patient risk principle of Article 17, referencing internationally accepted rules, and documenting the reasoning explicitly in the dossier so that reviewers can trace the logic rather than guess it.

4. Practical recommendations

1. Use an EU or IMDRF classification conclusion as the starting point, then re-verify it once against the potential patient risk principle of Article 17.
2. Write a standalone classification explanation page in the dossier, mapping intended use, contact duration and degree of invasiveness to the classification rules applied.
3. Assess IVD product lines SKU by SKU and issue a classification rationale for each, avoiding a one-size-fits-all conclusion for the whole line.
4. Where vigilance records exist in the country of origin or in Algeria, disclose them proactively in the dossier; do not count on the lighter assessment lane.
5. Once a classification conclusion has been filed, later changes must follow the change application route of Article 3 of the June 23, 2021 ministerial order; do not change it silently.
6. Prepare the classification explanation in both French and Arabic: French for the review, Arabic for checking packaging mock-ups.

5. Verification checklist

• □ A classification conclusion has been issued for every SKU under the four-class system of Article 17.
• □ The classification explanation maps intended use, contact duration and invasiveness to the rules applied.
• □ IVD product lines have been reasoned SKU by SKU, not as a single blanket conclusion.
• □ Vigilance records in the country of origin and in Algeria have been screened.
• □ Later changes to the classification are planned through the change application route.
• □ The classification explanation exists in French, and packaging mock-ups have been checked in Arabic.

Related reading in this series

• Article 02, Law 18-11 Articles 212 and 213: the definitional boundary of devices and IVDs — https://www.grzanglobal.com/algeria-medical-device-registration/law-18-11-article-212-213-device-ivd-definitions/
• Article 17, The regularization track: a fast route of 4-day admissibility plus a 90-day decision — https://www.grzanglobal.com/algeria-medical-device-registration/regularisation-fast-track-four-days-90-days/
• Article 13, The four phases of technical evaluation: Article 25 of Executive Decree 20-324 — https://www.grzanglobal.com/algeria-medical-device-registration/article-25-technical-evaluation-four-phases/

Regulatory information verified as of October 30, 2026.

GRZAN assists manufacturers with device classification strategy in Algeria, from SKU-level rationale and vigilance screening to dossier assembly and evaluation-pathway planning. For registration and compliance support in the Algerian market, contact info@grzanglobal.com.